| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/CIRCULATIONAHA.105.559724 |
| P698 | PubMed publication ID | 16380549 |
| P50 | author | Yung-Jue Bang | Q16180903 |
| Kwang Il Nam | Q42621591 | ||
| P2093 | author name string | Hae Jin Kee | |
| Hyun Kook | |||
| Jong-Keun Kim | |||
| Kyung Keun Kim | |||
| Nacksung Kim | |||
| Yong Ri Qian | |||
| Jonathan A Epstein | |||
| Myung Ho Jeong | |||
| Youngkeun Ahn | |||
| Zhan Yin | |||
| Il Suk Sohn | |||
| Jong Eun Park | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 51-59 | |
| P577 | publication date | 2005-12-27 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding | |
| P478 | volume | 113 |
| Q51687887 | A minimally invasive endovascular rabbit model for experimental induction of progressive myocardial hypertrophy. |
| Q38466095 | Activation of pyruvate dehydrogenase by dichloroacetate has the potential to induce epigenetic remodeling in the heart. |
| Q89006965 | Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology |
| Q90170910 | Angiotensin II represses Npr1 expression and receptor function by recruitment of transcription factors CREB and HSF-4a and activation of HDACs |
| Q34653312 | Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy |
| Q35723859 | Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure |
| Q41618085 | Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis |
| Q33772867 | Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats |
| Q38745611 | Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1. |
| Q34559028 | Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling |
| Q35252841 | Carbamazepine alone and in combination with doxycycline attenuates isoproterenol-induced cardiac hypertrophy |
| Q35040811 | Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension |
| Q37294656 | Caveolin induces cardioprotection through epigenetic regulation |
| Q38210525 | Chromatin modifications remodel cardiac gene expression |
| Q33969388 | Chromatin regulation by Brg1 underlies heart muscle development and disease |
| Q34814306 | Chromatin remodeling in cardiovascular development and physiology |
| Q64904280 | Chromatin remodelling and epigenetic state regulation by non-coding RNAs in the diseased heart. |
| Q33998649 | Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes |
| Q38692469 | Coordinating Regulation of Gene Expression in Cardiovascular Disease: Interactions between Chromatin Modifiers and Transcription Factors |
| Q56961844 | Crosstalk between FGF23- and angiotensin II-mediated Ca signaling in pathological cardiac hypertrophy |
| Q41986229 | Currying favor for the heart |
| Q36705529 | Derepression of pathological cardiac genes by members of the CaM kinase superfamily |
| Q36724656 | Drug discovery for heart failure: a new era or the end of the pipeline? |
| Q21284678 | Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases |
| Q34208448 | Early combined treatment with sildenafil and adipose-derived mesenchymal stem cells preserves heart function in rat dilated cardiomyopathy |
| Q33853732 | Early transcriptional alteration of histone deacetylases in a murine model of doxorubicin-induced cardiomyopathy |
| Q35758089 | Effect of the angiotensin II receptor blocker valsartan on cardiac hypertrophy and myocardial histone deacetylase expression in rats with aortic constriction |
| Q28082797 | Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series) |
| Q42076694 | Endothelin-stimulated human B-type natriuretic peptide gene expression is mediated by Yin Yang 1 in association with histone deacetylase 2. |
| Q57030935 | Epigallocatechin-3 gallate prevents pressure overload-induced heart failure by up-regulating SERCA2a via histone acetylation modification in mice |
| Q39182098 | Epigenetic Regulation: A New Frontier for Biomedical Engineers |
| Q34212728 | Epigenetic mechanisms in heart failure pathogenesis |
| Q38473339 | Epigenetic modifications and noncoding RNAs in cardiac hypertrophy and failure |
| Q92465956 | Epigenetics in Cardiac Hypertrophy and Heart Failure |
| Q39018712 | Epigenetics in Reactive and Reparative Cardiac Fibrogenesis: The Promise of Epigenetic Therapy |
| Q64880143 | Epigenetics in dilated cardiomyopathy. |
| Q88453278 | Epigenetics of Aberrant Cardiac Wound Healing |
| Q91251201 | Epigenetics, cardiovascular disease, and cellular reprogramming |
| Q37387804 | Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. |
| Q44515067 | Estrogen-related receptor gamma induces cardiac hypertrophy by activating GATA4. |
| Q86114271 | Exercise makes the difference: deconstructing physiological hypertrophy in swine |
| Q38124390 | From cell phenotype to epigenetic mechanisms: new insights into regenerating myocardium |
| Q37267318 | Genetics and epigenetics of arrhythmia and heart failure |
| Q34099442 | HDAC Inhibition Attenuates Inflammatory, Hypertrophic, and Hypertensive Responses in Spontaneously Hypertensive Rats |
| Q64084368 | HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases |
| Q26766640 | HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases |
| Q33891516 | HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation |
| Q36212830 | HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes |
| Q34769978 | HDAC inhibition elicits myocardial protective effect through modulation of MKK3/Akt-1. |
| Q35975931 | HDAC inhibition promotes cardiogenesis and the survival of embryonic stem cells through proteasome-dependent pathway |
| Q92324516 | HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis |
| Q36945016 | HDAC-dependent ventricular remodeling |
| Q35216855 | HDAC4 degradation mediates HDAC inhibition-induced protective effects against hypoxia/reoxygenation injury |
| Q28508698 | Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity |
| Q92132384 | Heart failure with preserved ejection fraction: present status and future directions |
| Q37281996 | Histone Deacetylase Inhibitor Phenylbutyrate Exaggerates Heart Failure in Pressure Overloaded Mice independently of HDAC inhibition. |
| Q35922922 | Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice |
| Q24603793 | Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy |
| Q34296712 | Histone deacetylase 1 reduces NO production in endothelial cells via lysine deacetylation of NO synthase 3. |
| Q39690407 | Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytes |
| Q41178134 | Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series). |
| Q35947882 | Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis |
| Q24568237 | Histone deacetylase signaling in cardioprotection |
| Q28569252 | Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury |
| Q34257607 | Histone deacetylase: a potential therapeutic target for fibrotic disorders |
| Q35893654 | Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility |
| Q27000389 | Histone deacetylases as targets for treatment of multiple diseases |
| Q28582424 | Histone deacetylases facilitate sodium/calcium exchanger up-regulation in adult cardiomyocytes |
| Q93056448 | Histone deacetylases in cardiovascular and metabolic diseases |
| Q37071681 | Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin |
| Q28579280 | Hyperoxia arrests alveolar development through suppression of histone deacetylases in neonatal rats |
| Q38311622 | Identification and visualization of stimulus-specific transcriptional activity in cardiac hypertrophy in mice |
| Q52728769 | Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. |
| Q37054939 | Immediate effects of a single exercise bout on protein O-GlcNAcylation and chromatin regulation of cardiac hypertrophy. |
| Q36626596 | Implication of abnormal epigenetic patterns for human diseases |
| Q39910687 | Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors |
| Q45063000 | Infusion of Valproic Acid Into the Renal Medulla Activates Stem Cell Population and Attenuates Salt-Sensitive Hypertension in Dahl S Rats |
| Q35671740 | Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and -9 expression and preserves LV function postmyocardial infarction |
| Q37417291 | Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. |
| Q36408024 | Inhibition of histone deacetylase-induced myocardial repair is mediated by c-kit in infarcted hearts |
| Q35847709 | Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis |
| Q36201061 | Irisin Ameliorates Hypoxia/Reoxygenation-Induced Injury through Modulation of Histone Deacetylase 4 |
| Q33392979 | Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart |
| Q37907323 | Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework. |
| Q38968198 | Kruppel-like factor 4 protein regulates isoproterenol-induced cardiac hypertrophy by modulating myocardin expression and activity |
| Q43281293 | Krüppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy |
| Q47668907 | Loss of cardiac carnitine palmitoyltransferase 2 results in rapamycin-resistant, acetylation-independent hypertrophy. |
| Q36541232 | MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification |
| Q43012174 | Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice |
| Q38932625 | Mechanisms of transcription factor acetylation and consequences in hearts. |
| Q89909438 | MicroRNA-489 suppresses isoproterenol-induced cardiac fibrosis by downregulating histone deacetylase 2 |
| Q64999485 | Myocyte-specific overexpressing HDAC4 promotes myocardial ischemia/reperfusion injury. |
| Q42702677 | New Aspects of Vascular Calcification: Histone Deacetylases and Beyond. |
| Q35695849 | Non-sirtuin histone deacetylases in the control of cardiac aging |
| Q90290390 | Novel Insight Into the Epigenetic and Post-transcriptional Control of Cardiac Gene Expression by Thyroid Hormone |
| Q26765152 | Novel epigenetic-based therapies useful in cardiovascular medicine |
| Q52793543 | Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts. |
| Q57174535 | PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart |
| Q28265173 | Pathogenic properties of the N-terminal region of cardiac myosin binding protein-C in vitro |
| Q38090679 | Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases |
| Q28554628 | Piceatannol Attenuates Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Downregulation of Histone Deacetylase 4/5 or p38-MAPK Signaling |
| Q35485587 | Potential non-oncological applications of histone deacetylase inhibitors |
| Q34685319 | Pressure overload-induced cardiac hypertrophy response requires janus kinase 2-histone deacetylase 2 signaling |
| Q37303806 | Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300. |
| Q35757916 | Re-employment of developmental transcription factors in adult heart disease |
| Q35234488 | Readers, writers, and erasers: chromatin as the whiteboard of heart disease |
| Q33825179 | Redundant control of adipogenesis by histone deacetylases 1 and 2 |
| Q46762873 | Regulation of Oxidative Stress in Pulmonary Artery Endothelium. Modulation of Extracellular Superoxide Dismutase and NOX4 Expression Using Histone Deacetylase Class I Inhibitors |
| Q29615166 | Regulation of cardiac hypertrophy by intracellular signalling pathways |
| Q35683079 | Regulation of peroxisome proliferator-activated receptor-γ by angiotensin II via transforming growth factor-β1-activated p38 mitogen-activated protein kinase in aortic smooth muscle cells |
| Q37139674 | Retinoic acid and sodium butyrate suppress the cardiac expression of hypertrophic markers and proinflammatory mediators in Npr1 gene-disrupted haplotype mice |
| Q44843409 | Right ventricular myocardial performance index is decreased with severe pressure-overload cardiac hypertrophy in young rats |
| Q35676378 | Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy |
| Q35517710 | Roles and post-translational regulation of cardiac class IIa histone deacetylase isoforms. |
| Q34383040 | Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy |
| Q38972184 | Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy |
| Q64889213 | Selective inhibition of histone deacetylase 8 improves vascular hypertrophy, relaxation, and inflammation in angiotensin II hypertensive mice. |
| Q64992782 | Short-Chain Fatty Acid Propionate Protects From Hypertensive Cardiovascular Damage. |
| Q26825154 | Signaling effectors underlying pathologic growth and remodeling of the heart |
| Q33916456 | Significance of thymosin β4 and implication of PINCH-1-ILK-α-parvin (PIP) complex in human dilated cardiomyopathy |
| Q36887547 | Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface |
| Q46429786 | Sodium Butyrate Protects -Against High Fat Diet-Induced Cardiac Dysfunction and Metabolic Disorders in Type II Diabetic Mice |
| Q34062891 | Specific inhibition of HDAC4 in cardiac progenitor cells enhances myocardial repairs |
| Q24289391 | Stable protein, unstable plaque? |
| Q64122646 | Structural and functional cardiac profile after prolonged duration of mechanical unloading: potential implications for myocardial recovery |
| Q33929939 | Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy |
| Q36800026 | Synergistic induction of miR-126 by hypoxia and HDAC inhibitors in cardiac myocytes |
| Q37876521 | Tapping the brake on cardiac growth-endogenous repressors of hypertrophic signaling |
| Q33917016 | Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition |
| Q38196176 | Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs. |
| Q37494673 | Targeting histone deacetylases for heart failure |
| Q28085588 | Targeting histone deacetylases: perspectives for epigenetic-based therapy in cardio-cerebrovascular disease |
| Q35016989 | Targeting inflammation in heart failure with histone deacetylase inhibitors |
| Q36226378 | Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity |
| Q92344377 | The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models |
| Q60927794 | The Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart |
| Q34277801 | The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model |
| Q26852614 | The emerging role of epigenetics in cardiovascular disease |
| Q38328034 | The expanding role of epigenetics. |
| Q28586308 | The primary microRNA-208b interacts with Polycomb-group protein, Ezh2, to regulate gene expression in the heart |
| Q43024151 | Transcriptional changes associated with recovery from heart failure in the SHR. |
| Q41836714 | Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy |
| Q57027840 | Transgenic overexpression of active HDAC4 in the heart attenuates cardiac function and exacerbates remodeling in infarcted myocardium |
| Q87207661 | Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes |
| Q33994818 | Vascular histone deacetylation by pharmacological HDAC inhibition |
| Q33892798 | gp-91 mediates histone deacetylase inhibition-induced cardioprotection |
| Q41693992 | miR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8. |
Search more.